Pasithea Therapeutics Corp.(KTTA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KTTA Pasithea Therapeutics Corp.

交易中 09-30 15:26:20 EDT

0.4810

-0.0090

-1.84%

最高0.5000	最低0.4769	成交量6,585
今开0.4893	昨收0.4900	日振幅4.71%
总市值1,607万	流通市值490.72万	总股本3,341万
成交额3,201	换手率0.06%	流通股本1,020万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.481,"timestamp":1790795741066,"preClose":0.49,"halted":0,"volume":6585,"delay":0,"changeRate":-0.018367346938775526,"floatShares":10202000,"shares":33414448,"eps":-1.482,"marketStatus":"交易中","change":-0.009,"latestTime":"09-30 15:26:20 EDT","open":0.4893,"high":0.5,"low":0.4769,"amount":3201.12502545,"amplitude":0.047143,"askPrice":0.4997,"askSize":100,"bidPrice":0.4806,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.482,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790798400000},"marketStatusCode":2,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.49,"postHourTrading":{"tag":"盘后","latestPrice":0.461,"preClose":0.49,"latestTime":"17:22 EDT","volume":2256,"amount":1040.19,"timestamp":1790716973324,"change":-0.029,"changeRate":-0.059184,"amplitude":0.059184},"volumeRatio":0.059297},"requestUrl":"/m/hq/s/KTTA/tweets","defaultTab":"tweets","newsList":[{"id":"1135437332","title":"Pasithea Therapeutics公布一期晚期癌症研究积极中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1135437332","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135437332?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:27","pubTimestamp":1783322876,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp.宣布，其针对晚期癌症的一期研究获得了积极的中期数据，结果显示在经MEK/BRAF预处理的患者中，其药物展现出长期安全性、耐受性以及持久的临床活性。公司同时宣布了研究方案的扩展计划。\n数据显示，候选药物PAS-4展现出良好的安全性特征，仅观察到1级或2级不良事件。此外，研究方案已获修订，将PAS-4的剂量递增范围扩展至最高52毫克。\n为进一步评估药物特性，公司已启动一项关于PAS-4药代动力学的初步食物效应研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157322460","title":"Pasithea Therapeutics公司旗下药物Pas-4展现良好安全性，仅出现1级或2级不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1157322460","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157322460?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:02","pubTimestamp":1782817361,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. 宣布，其候选药物Pas-4在临床研究中表现出良好的安全性特征。数据显示，所有观察到的药物相关不良事件均为1级或2级，未出现更高级别（3级及以上）的安全性事件。\n这一积极的安全数据为Pas-4的后续临床开发奠定了重要基础。通常，药物在早期临床试验中展现出可控的安全性，是推进至更后期研究阶段的关键前提。投资者和分析师普遍关注生物技术公司候选药物的安全性，因为这直接影响其监管审批前景和商业化潜力。\n公司表示，将继续推进Pas-4的相关研究计划，并评估其在目标适应症中的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107499570","title":"Pasithea Therapeutics公布积极1期中期研究数据，显示长期安全耐受性及在Mek/Braf预处理患者中的持久临床活性，并宣布方案扩展","url":"https://stock-news.laohu8.com/highlight/detail?id=1107499570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107499570?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:02","pubTimestamp":1782817333,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics公司宣布了其针对晚期癌症的1期研究积极中期数据。数据显示，其疗法在长期安全性与耐受性方面表现良好，并在接受过Mek/Braf抑制剂预处理的患者群体中展现出持久的临床活性。基于这些积极结果，公司已决定扩展研究方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105680375","title":"帕西莎治疗公司修正方案：治疗期延至18个月，新增核磁共振与认知测量","url":"https://stock-news.laohu8.com/highlight/detail?id=1105680375","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105680375?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:04","pubTimestamp":1781607863,"startTime":"0","endTime":"0","summary":"帕西莎治疗公司（Pasithea Therapeutics Corp.）宣布，对其治疗方案进行了重要修正。根据最新调整，患者治疗周期将延长至18个月，并新增了核磁共振扫描与认知测量两项关键评估内容。这一系列修正旨在更全面地监测治疗效果与患者长期状况，为临床研究提供更为详尽的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169450760","title":"Pasithea Therapeutics：修订方案增加24毫克与32毫克剂量组，并补充I/IB期试验队列","url":"https://stock-news.laohu8.com/highlight/detail?id=1169450760","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169450760?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:03","pubTimestamp":1781607800,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. 宣布对其正在进行的I/IB期临床试验方案进行修订。此次修订的核心内容包括引入两个更高的剂量水平——24毫克与32毫克，并对现有队列进行补充入组。这一调整旨在更全面地评估研究药物的安全性与耐受性，同时探索其潜在疗效。公司表示，方案的修订是基于对现有数据审慎分析后的决定，以期优化试验设计，加速临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139970739","title":"Pasithea Therapeutics宣布修订1/1B期Nf1临床试验研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1139970739","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139970739?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:01","pubTimestamp":1781607695,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics公司近日宣布，已对其正在进行的1/1B期神经纤维瘤病1型临床试验的研究方案进行了修订。此次修订旨在优化试验设计，以更有效地评估候选疗法的安全性与潜在疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167513027","title":"Pasithea Therapeutics宣布其药物Pas-004获FDA孤儿药认定，用于治疗肌萎缩侧索硬化症(ALS)","url":"https://stock-news.laohu8.com/highlight/detail?id=1167513027","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167513027?lang=zh_cn&edition=full","pubTime":"2026-06-02 19:04","pubTimestamp":1780398262,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics公司宣布，美国食品药品监督管理局已授予其候选药物Pas-004孤儿药认定，用于治疗肌萎缩侧索硬化症。对于Pasithea Therapeutics而言，这一认定是推进其ALS治疗管线的重要一步。肌萎缩侧索硬化症是一种进行性神经退行性疾病，目前治疗方案有限，存在大量未满足的医疗需求。公司表示，将继续推进Pas-004的临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102952162","title":"Pasithea Therapeutics获FDA授予罕见儿科疾病认定 RPDD 予PAS-004用于治疗1型神经纤维瘤病","url":"https://stock-news.laohu8.com/highlight/detail?id=1102952162","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102952162?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:08","pubTimestamp":1776683330,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. 宣布，其研发药物PAS-004已获得美国食品药品监督管理局授予的罕见儿科疾病认定，该药物拟用于治疗1型神经纤维瘤病。这一认定标志着PAS-004在针对儿童罕见病治疗领域的研发进程中迈出了重要一步。获得RPDD资格意味着，若PAS-004后续获得新药上市批准，该公司将有资格获得一张优先审评券。1型神经纤维瘤病是一种遗传性神经系统疾病，主要表现为皮肤色素斑和神经纤维瘤的形成。PAS-004作为一种创新疗法，其研发进展为患者群体带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145086968","title":"Pasithea Therapeutics获FDA授予快速通道资格，Pas-004有望治疗I型神经纤维瘤病相关丛状神经纤维瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1145086968","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145086968?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:04","pubTimestamp":1775041499,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp.（以下简称\"Pasithea\"）宣布，其研发的药物Pas-004已获得美国食品药品监督管理局（FDA）授予的快速通道资格。该药物旨在治疗I型神经纤维瘤病（Nf1）相关的丛状神经纤维瘤（Pn），此类肿瘤可导致显著的发病率和严重健康问题。\n快速通道资格的授予将加速Pas-004的研发和审评进程，为患者提供更早获得创新疗法的可能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518205086","title":"Pasithea Therapeutics Corp.盘中异动 大幅下跌9.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518205086","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518205086?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:39","pubTimestamp":1741628391,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时39分，Pasithea Therapeutics Corp.股票出现波动，股价急速下挫9.24%。截至发稿，该股报1.08美元/股，成交量7371股，换手率0.58%，振幅3.84%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.87%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5288.34%、3824.05%、989.31%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、58.34%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031101395296406773&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031101395296406773&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517974591","title":"Pasithea Therapeutics Corp.盘中异动 下午盘急速下跌7.14%报1.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517974591","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517974591?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:18","pubTimestamp":1741292296,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日04时18分，Pasithea Therapeutics Corp.股票出现异动，股价急速下跌7.14%。截至发稿，该股报1.17美元/股，成交量1.1446万股，换手率0.90%，振幅2.38%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体跌幅为1.11%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307041816963c8861&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307041816963c8861&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517692884","title":"Pasithea Therapeutics Corp.盘中异动 急速拉升9.26%报1.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517692884","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517692884?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:10","pubTimestamp":1741198202,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时10分，Pasithea Therapeutics Corp.股票出现异动，股价急速拉升9.26%。截至发稿，该股报1.18美元/股，成交量9.0355万股，换手率7.13%，振幅12.96%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为1.34%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为946.41%、305.29%、300.32%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306021002abe9ef7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306021002abe9ef7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516665617","title":"Pasithea Therapeutics Corp.盘中异动 股价大跌5.17%报1.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665617","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516665617?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:00","pubTimestamp":1741035659,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日05时00分，Pasithea Therapeutics Corp.股票出现异动，股价急速下挫5.17%。截至发稿，该股报1.10美元/股，成交量3.5017万股，换手率2.77%，振幅6.22%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体跌幅为0.20%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4718.81%、220.92%、191.83%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304050059963802d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304050059963802d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514336386","title":"Pasithea Therapeutics Corp.盘中异动 下午盘股价大跌5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514336386","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514336386?lang=zh_cn&edition=full","pubTime":"2025-02-28 02:11","pubTimestamp":1740679887,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日02时11分，Pasithea Therapeutics Corp.股票出现异动，股价快速跳水5.41%。截至发稿，该股报1.22美元/股，成交量1.9906万股，换手率1.57%，振幅3.01%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Pepgen Inc.、Cingulate Inc C/Wts 10/12/2026 、Ibio, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1759.85%、309.62%、131.27%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Pepgen Inc.，振幅分别为86.14%、55.19%、52.29%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280211279632db6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280211279632db6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514847865","title":"Pasithea Therapeutics Corp.盘中异动 股价大涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514847865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514847865?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:26","pubTimestamp":1740590789,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日01时26分，Pasithea Therapeutics Corp.股票出现异动，股价急速拉升5.65%。截至发稿，该股报1.22美元/股，成交量4.0598万股，换手率3.21%，振幅5.22%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6122.39%、233.09%、223.02%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Pds Biotechnology Corporation，振幅分别为194.07%、49.18%、44.44%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022701262996316fd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022701262996316fd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514019090","title":"Pasithea Therapeutics Corp.盘中异动 早盘股价大跌5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514019090","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514019090?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:11","pubTimestamp":1740499893,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时11分，Pasithea Therapeutics Corp.股票出现波动，股价急速跳水5.56%。截至发稿，该股报1.19美元/股，成交量3.1777万股，换手率2.51%，振幅3.17%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.63%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1269.33%、1103.05%、869.48%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Adial Pharmaceuticals, Inc，振幅分别为224.93%、87.83%、64.05%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001133a2539dff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001133a2539dff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514761657","title":"Pasithea Therapeutics Corp.盘中异动 股价大跌6.15%报1.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514761657","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514761657?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:50","pubTimestamp":1740412229,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时50分，Pasithea Therapeutics Corp.股票出现异动，股价大幅跳水6.15%。截至发稿，该股报1.22美元/股，成交量13.0879万股，换手率10.33%，振幅6.92%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为231.75%、98.54%、28.36%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为151.09%、55.69%、53.34%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235029962eab26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235029962eab26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512671486","title":"Pasithea Therapeutics Corp.盘中异动 早盘急速下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512671486","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512671486?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:11","pubTimestamp":1739977870,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时11分，Pasithea Therapeutics Corp.股票出现波动，股价大幅跳水5.02%。截至发稿，该股报1.30美元/股，成交量3.2788万股，换手率2.59%，振幅2.92%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 、Aditxt, Inc.涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为408.63%、228.62%、109.88%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.、Allogene Therapeutics, Inc.，振幅分别为207.68%、136.98%、36.97%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219231110a24c042a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219231110a24c042a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512692631","title":"Pasithea Therapeutics Corp.盘中异动 股价大跌5.47%报1.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512692631","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512692631?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:19","pubTimestamp":1739891983,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时19分，Pasithea Therapeutics Corp.股票出现波动，股价快速跳水5.47%。截至发稿，该股报1.37美元/股，成交量3.7194万股，换手率2.94%，振幅7.54%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.81%。其相关个股中，Allogene Therapeutics, Inc.、Solid Biosciences Inc.、Pulmatrix, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为355.07%、137.44%、135.47%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Allogene Therapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 ，振幅分别为148.75%、54.17%、51.40%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218231943abd3ba44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218231943abd3ba44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511696290","title":"Pasithea Therapeutics Corp.盘中异动 大幅上涨5.34%报1.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511696290","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511696290?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:43","pubTimestamp":1739544195,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时43分，Pasithea Therapeutics Corp.股票出现异动，股价急速拉升5.34%。截至发稿，该股报1.54美元/股，成交量2.7685万股，换手率2.19%，振幅4.79%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.39%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为1537.63%、439.12%、406.47%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Klotho Neurosciences, Inc.，振幅分别为55.12%、32.93%、32.49%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422431598858c8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422431598858c8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pasithea.com","stockEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.125},{"period":"3month","weight":-0.1357},{"period":"6month","weight":-0.3636},{"period":"1year","weight":-0.3194},{"period":"ytd","weight":-0.6202}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pasithea Therapeutics Corp.于2020年5月12日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，专注于发现、研究和开发针对中枢神经系统疾病和其他疾病的创新疗法，包括RASopathies。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.182441},{"month":2,"riseRate":0.4,"avgChangeRate":-0.152614},{"month":3,"riseRate":0.4,"avgChangeRate":-0.0152},{"month":4,"riseRate":0.2,"avgChangeRate":0.004803},{"month":5,"riseRate":0.4,"avgChangeRate":-0.176425},{"month":6,"riseRate":0.4,"avgChangeRate":-0.006229},{"month":7,"riseRate":0.8,"avgChangeRate":0.060824},{"month":8,"riseRate":0.6,"avgChangeRate":0.04667},{"month":9,"riseRate":0.4,"avgChangeRate":-0.032417},{"month":10,"riseRate":0.2,"avgChangeRate":-0.132455},{"month":11,"riseRate":0.4,"avgChangeRate":0.147256},{"month":12,"riseRate":0.4,"avgChangeRate":-0.165941}],"exchange":"NASDAQ","name":"Pasithea Therapeutics Corp.","nameEN":"Pasithea Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pasithea Therapeutics Corp.(KTTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pasithea Therapeutics Corp.(KTTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pasithea Therapeutics Corp.,KTTA,Pasithea Therapeutics Corp.股票,Pasithea Therapeutics Corp.股票老虎,Pasithea Therapeutics Corp.股票老虎国际,Pasithea Therapeutics Corp.行情,Pasithea Therapeutics Corp.股票行情,Pasithea Therapeutics Corp.股价,Pasithea Therapeutics Corp.股市,Pasithea Therapeutics Corp.股票价格,Pasithea Therapeutics Corp.股票交易,Pasithea Therapeutics Corp.股票购买,Pasithea Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pasithea Therapeutics Corp.(KTTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pasithea Therapeutics Corp.(KTTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}